Study of RMC-6291 in Combination with RMC-6236 in Participants with Advanced KRAS G12C Mutant Solid Tumors

Description

This study is to evaluate the safety, tolerability, and PK profiles of RMC-6291 and RMC-6236 in adults with KRAS G12C-mutated solid tumors.

Conditions

Non-Small Cell Lung Cancer (NSCLC), Colorectal Cancer, Pancreatic Ductal Adenocarcinoma

Talk to us

Study Overview

On this page

Study Details

Study overview

This study is to evaluate the safety, tolerability, and PK profiles of RMC-6291 and RMC-6236 in adults with KRAS G12C-mutated solid tumors.

Phase 1b, Multicenter, Open-Label, Dose Escalation and Dose Expansion Study of RMC-6291 in Combination with RMC-6236 in Participants with Advanced KRAS G12C Mutant Solid Tumors

Study of RMC-6291 in Combination with RMC-6236 in Participants with Advanced KRAS G12C Mutant Solid Tumors

Condition
Non-Small Cell Lung Cancer (NSCLC)
Intervention / Treatment

-

Contacts and Locations

Duarte

City of Hope, Duarte, California, United States, 91010

Orange

UC IRVINE Health, Orange, California, United States, 92868

Sacramento

UC Davis Comprehensive Cancer Center, Sacramento, California, United States, 95817

Stanford

Stanford Cancer Institute, Stanford, California, United States, 94305

Aurora

University of Colorado Cancer Center, Aurora, Colorado, United States, 80045

Sarasota

Florida Cancer Specialists, Sarasota, Florida, United States, 34232

Tampa

Moffitt Cancer Center and Research Institute, Tampa, Florida, United States, 33612

Boston

Dana Farber Cancer Institute, Boston, Massachusetts, United States, 02215

Detroit

Henry Ford Cancer, Detroit, Michigan, United States, 48202

Grand Rapids

START Midwest, Grand Rapids, Michigan, United States, 49546

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

For general information about clinical research, read Learn About Studies.

Eligibility Criteria

  • * 18 years of age
  • * Histology: pathologically documented, KRAS G12C-mutated, advanced or metastatic solid tumors not amendable to curative therapy
  • 1. Part 1. Dose Escalation: solid tumors, previously treated
  • 2. Part 2. Dose Expansion:
  • * ECOG performance status 0 or 1
  • * Adequate organ function
  • * Primary central nervous system (CNS) tumors
  • * Active brain metastases
  • * Known impairment of GI function that would alter the absorption
  • * Major surgical procedures within 28 days or non-study related minor procedures within 7 days of treatment

Ages Eligible for Study

18 Years to 125 Years

Sexes Eligible for Study

ALL

Accepts Healthy Volunteers

No

Collaborators and Investigators

Revolution Medicines, Inc.,

Revolution Medicines, Inc., STUDY_DIRECTOR, Revolution Medicines, Inc.

Study Record Dates

2026-11-30